A5033528208- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Systemic Lupus Erythematosus Research
- Inflammatory Biomarkers in Disease Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Immune Cell Function and Interaction
- Pancreatic and Hepatic Oncology Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Neuroendocrine Tumor Research Advances
- Inflammatory Myopathies and Dermatomyositis
- T-cell and B-cell Immunology
- Cancer Cells and Metastasis
- Epigenetics and DNA Methylation
- Immune cells in cancer
- Nutrition and Health in Aging
- Tryptophan and brain disorders
- Membrane Separation Technologies
- Monoclonal and Polyclonal Antibodies Research
- Esophageal Cancer Research and Treatment
- Immunotherapy and Immune Responses
- Brain Metastases and Treatment
Saiseikai Fukuoka General Hospital
2021-2025
Institute of Science Tokyo
2025
Tokyo Medical and Dental University
2011-2024
Hitachi (Japan)
2024
Yokohama National University
2024
Kitakyushu Municipal Medical Center
2020-2022
National Hospital Organization Kyushu Cancer Center
2017-2021
Yamaguchi University
2021
Kyushu University
2014-2021
The University of Tokyo
2016-2021
Abstract Objective To assess the safety of interleukin‐6 receptor inhibition and to collect preliminary data on clinical immunologic efficacy tocilizumab in patients with systemic lupus erythematosus (SLE). Methods In an open‐label phase I dosage‐escalation study, 16 mild‐to‐moderate disease activity were assigned receive 1 3 doses given intravenously every other week for 12 weeks (total 7 infusions): 2 mg/kg 4 patients, 6 or 8 patients. Patients then monitored additional weeks. Results The...
Abstract Objective Immunosuppressive agents have become the standard of therapy for proliferative lupus nephritis, but some patients may relapse after discontinuing treatment. We reviewed cases renal flares in a cohort who participated 2 randomized controlled clinical trials at National Institutes Health and explored prevalence, outcome, predictive factors flares. Methods Data were obtained on 145 treated with pulse cyclophosphamide, methylprednisolone, or combination both. Patients had not...
Abstract Objective To assess the association of cognitive dysfunction and depression with serum antibodies to N ‐methyl‐ D ‐aspartate (NMDA) receptor (anti‐NR2) analyze clinical neuroimaging correlates in patients systemic lupus erythematosus (SLE). Methods Sixty underwent neurocognitive assessment, evaluation for Beck Depression Inventory II (BDI‐II) psychiatric interview (Diagnostic Statistical Manual Mental Disorders, Fourth Edition [DSM‐IV] criteria), brain magnetic resonance imaging,...
Systemic lupus erythematosus (SLE) is an autoimmune disease that causes multiple organ damage. Although recent genome-wide association studies (GWAS) have contributed to discovery of SLE susceptibility genes, few has been performed in Asian populations. Here, we report a GWAS for examining 891 cases and 3,384 controls multi-stage replication 1,387 28,564 Japanese subjects. Considering expression quantitative trait loci (eQTLs) implicated genetic risks diseases, integrated eQTL study into the...
The gastrointestinal microbiota was reported as an important factor for the response to cancer immunotherapy. Probiotics associated with dysbiosis and bacterial richness may affect efficacy of immunotherapy drugs. However, clinical impact probiotics on in patients nonsmall cell lung (NSCLC) is poorly understood. outcomes 294 advanced or recurrent NSCLC who received antiprogrammed death-1 (PD-1) therapy (nivolumab pembrolizumab monotherapy) at three medical centers Japan were analyzed our...
Abstract Objective The hyperimmunoglobulinemia D and periodic fever syndrome (HIDS; MIM 260920) is caused by recessive mutations in the mevalonate kinase gene ( MVK ), which encodes an enzyme involved cholesterol nonsterol isoprenoid biosynthesis. HIDS characterized persistently elevated polyclonal IgD recurrent febrile episodes. Although abnormalities tumor necrosis factor α (TNFα) are not primary cause of HIDS, plasma TNFα levels patients during attacks thus may be a therapeutic target....
Abstract Objective Pulse cyclophosphamide is the treatment of choice for severe lupus nephritis. However, not all patients respond to this therapy, and gonadal toxicity particular concern. Cyclophosphamide a prodrug that requires activation by cytochrome P450 (CYP) enzymes. We conducted retrospective cohort study test whether genetic polymorphisms these enzymes are associated with of, clinical response to, in Methods Sixty‐two proliferative nephritis treated were genotyped common variant...
Disturbances in peripheral blood memory B cell subpopulations have been observed various autoimmune diseases, but not fully delineated rheumatoid arthritis (RA). Additionally, the possible role of tumour necrosis factor (TNF) regulating changes specific subsets RA is still unclear.
Abstract Introduction Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it thought that these might contribute to pathogenesis RA by antigen presentation, autoantibody production, and/or inflammatory cytokine production. Chemokines could enhance accumulation synovium. The aims this study were determine chemokine receptor expression both peripheral blood normal donors subjects with RA, at site effects chemokines on cell activation. Methods Cell surface...
Although corticosteroids and immunosuppressants are widely used for the treatments of systemic lupus erythematosus (SLE), safer more effective therapies prerequisite. We others have reported that anti-CD20 antibody rituximab targeting B cells refractory SLE and, therefore, safety clinical efficacy in was evaluated by a multicenter phase I/II trial. An open-label, study 15 patients with active (total British Isles Lupus Assessment Group [BILAG] score 8 to 17) conducted. Rituximab administered...
Abstract Programmed cell death‐1 ( PD ‐1) and programmed death‐ligand 1 ‐L1) have been identified as novel targets of immunotherapy lung cancer. In present study, we evaluated the metabolic characteristics cancer by using 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography F‐ FDG PET / CT ) with regard to ‐L1 protein expression. expression was immunohistochemistry antibody clone SP 142 in 579 surgically resected primary patients. Cases less than 5% tumor membrane...
Background: The prognostic Controlling Nutritional Status (CONUT) score is used to evaluate immuno-nutritional conditions and a predictive factor of postoperative survival in patients with digestive tract cancer. We retrospectively analyzed clinicopathological features pathological stage I non-small cell lung cancer (NSCLC) identify predictors or factors investigate the role preoperative CONUT predicting survival. Patients Methods: selected 138 consecutive NSCLC treated from August 2005...
Background: The preoperative immune-nutritional status has been shown to predict the postoperative prognosis in various types of cancer; however, prognostic significance controlling nutritional (CONUT) score resected lung squamous cell carcinoma (SCC) yet be elucidated. Methods: A total 108 patients with SCC were analyzed for their clinicopathological factors, including CONUT score, which can calculated from serum albumin, cholesterol, and peripheral lymphocyte count. divided into two...
The world's population is rapidly ageing, and the age of patients with lung cancer will increase as well. prognostic nutritional index, controlling status geriatric risk index (GNRI) are useful parameters for evaluating immune-nutritional status. We aimed to perform a multicentre retrospective study investigate correlations these postoperative comorbidities or surgical outcomes elderly non-small-cell (NSCLC).We selected 272 consecutive NSCLC aged >75 years treated from January 2005 December...